Press Release << Back Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation
CARLSBAD, Calif., Dec. 20, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What:
Isis Pharmaceuticals' R&D Webcast Presentation
When:
Thursday, January 05, 2012 at 9:00 a.m. PT / 12:00 p.m. ET
Where:
www.isispharm.com
How:
Live on the Internet. Simply log on to our Web site listed above.
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com. .................................. GENZYME plans to COMMERCIALIZE MIPOMERSEN IN @2012...VALADATING ATL1101,1102,1103!!!!!
Genzyme plans to commercialize MIPOMERSEN in 2012..
ANP Price at posting:
23.0¢ Sentiment: ST Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)